Portage Biotech Provides Research and Development Update and Announces NASDAQ Listing Approval
Company to advance three clinical-stage programs in pipeline - Portage has received approval and is preparing for NASDAQ listing –Portage Biotech Inc. today announced its 2021 research and development goals, including advancing three of its pipeline assets through clinical trials during the upcoming year. Portage also announced that it has received approval from the NASDAQ Capital Market to list its common … Company to advance three clinical-stage programs in pipeline Portage has received approval and is preparing for NASDAQ listing
Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) (“Portage” or the “Company”) today announced its 2021 research and development goals, including advancing three of its pipeline assets through clinical trials during the upcoming year. Portage also announced that it has received approval from the NASDAQ Capital Market (“NASDAQ”) to
FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to note that Portage Biotech Inc. ( Portage ) has today announced its 2021 research and development goals , including advancing three of its pipeline assets through clinical trials during the upcoming year. Portage also announced that it has received approval from the NASDAQ Capital Market ( NASDAQ ) to list its common shares on the NASDAQ exchange, and expects to commence trading on 25 February 2021 under the symbol PRTG . FastForward has a 0.56% interest in the issued stock of Portage. Ed McDermott, CEO of FastForward Innovations, commented: